Ticker: AKTX

Akari Therapeutics, Plc (NASDAQ: AKTX) recently released its quarterly financial results for the period ending March 31, 2025. Below are key insights from the company's income statement and recent developments. Income Statement Highlights: Total Operating Expenses: $3.5 million for Q1 2025, down...